Nuria Romero-Laorden1, David Olmos1, Tanja Fehm2, Jesus Garcia-Donas1, Ivan Diaz-Padilla3. 1. Division of Medical Oncology, Centro Integral Oncológico Clara Campal, Hospital Universitario HM Sanchinarro, Madrid, Spain; Clinical Research Program, Centro Nacional de Investigaciones Oncologicas, Madrid, Spain. 2. Department of Obstetrics and Gynecology, University of Düsseldorf, Düsseldorf, Germany. 3. Division of Medical Oncology, Centro Integral Oncológico Clara Campal, Hospital Universitario HM Sanchinarro, Madrid, Spain. Electronic address: drdiazpadilla@me.com.
Abstract
OBJECTIVES: Detecting circulating tumor cells (CTCs) in the peripheral blood and disseminated tumor cells (DTCs) in the bone marrow of cancer patients has proven feasible and of prognostic value in different neoplasms. However, the clinical significance of CTCs and DTCs in ovarian cancer and its association with outcome remains unclear. METHODS: A literature search in PubMed was performed from January 2000 to December 2013 for studies evaluating CTCs and/or DTCs and its association with clinicopathological characteristics and clinical outcome in ovarian cancer. The main outcome measures were progression-free survival (PFS) and overall survival (OS). RESULTS: Fourteen studies met the inclusion criteria. Median study size was 84 patients (range 43-216). Median follow-up was 19months (range 5-52). Most studies were small case series (n<100; studies; 71%). The majority of studies used an immunophenotyping approach to identify CTCs and/or DTCs, but only 3 studies (21%) used the FDA-approved Cell Search method. Despite the differences in methodology among studies the presence of CTCs and DTCs tended to be associated with higher baseline CA-125 serum levels, higher odds of residual disease after surgery, and worse survival in ovarian cancer across studies. No consistent intra-patient correlation was observed between DTCs detected in the bone marrow and CTCs detected in the blood. CONCLUSIONS: The presence of CTCs and DTCs is associated with adverse clinicopathological characteristics and poor clinical outcomes in ovarian cancer patients. Its implementation as a valuable prognostic tool in the clinical setting requires uniform methodology and prospective validation.
OBJECTIVES: Detecting circulating tumor cells (CTCs) in the peripheral blood and disseminated tumor cells (DTCs) in the bone marrow of cancerpatients has proven feasible and of prognostic value in different neoplasms. However, the clinical significance of CTCs and DTCs in ovarian cancer and its association with outcome remains unclear. METHODS: A literature search in PubMed was performed from January 2000 to December 2013 for studies evaluating CTCs and/or DTCs and its association with clinicopathological characteristics and clinical outcome in ovarian cancer. The main outcome measures were progression-free survival (PFS) and overall survival (OS). RESULTS: Fourteen studies met the inclusion criteria. Median study size was 84 patients (range 43-216). Median follow-up was 19months (range 5-52). Most studies were small case series (n<100; studies; 71%). The majority of studies used an immunophenotyping approach to identify CTCs and/or DTCs, but only 3 studies (21%) used the FDA-approved Cell Search method. Despite the differences in methodology among studies the presence of CTCs and DTCs tended to be associated with higher baseline CA-125 serum levels, higher odds of residual disease after surgery, and worse survival in ovarian cancer across studies. No consistent intra-patient correlation was observed between DTCs detected in the bone marrow and CTCs detected in the blood. CONCLUSIONS: The presence of CTCs and DTCs is associated with adverse clinicopathological characteristics and poor clinical outcomes in ovarian cancerpatients. Its implementation as a valuable prognostic tool in the clinical setting requires uniform methodology and prospective validation.
Authors: Katarina Kolostova; Rafał Matkowski; Marcin Jędryka; Katarzyna Soter; Martin Cegan; Michael Pinkas; Anna Jakabova; Jiri Pavlasek; Jan Spicka; Vladimir Bobek Journal: Am J Cancer Res Date: 2015-10-15 Impact factor: 6.166
Authors: Maurizio Romano; Francesco De Francesco; Giuseppe Pirozzi; Enrico Gringeri; Riccardo Boetto; Marina Di Domenico; Barbara Zavan; Giuseppe A Ferraro; Umberto Cillo Journal: Oncoscience Date: 2015-05-15
Authors: Eva Obermayr; Natalia Bednarz-Knoll; Beatrice Orsetti; Heinz-Ulrich Weier; Sandrina Lambrechts; Dan Cacsire Castillo-Tong; Alexander Reinthaller; Elena Ioana Braicu; Sven Mahner; Jalid Sehouli; Ignace Vergote; Charles Theillet; Robert Zeillinger; Burkhard Brandt Journal: Oncotarget Date: 2017-11-16